Therapeutic advantages of omega-3 fatty acid supplementation in patients with schizophrenia – a systematic review

Obrazek miniatury
Vityala, Srilaxmi
Kanteti, Krishna Priya
Vityala, Yethindra
Tagaev, Tugolbai
Damineni, Ujwala
Tytuł czasopisma
Tytuł tomu
Publishing Office of the University of Rzeszow
Introduction and aim. In patients with schizophrenia, omega-3 (n-3) polyunsaturated fatty acids (PUFAs) treatment was found to ameliorate the cardiovascular, metabolic, and inflammatory problems caused by antipsychotic medication and even reduce the need for medication by 20%. In this study, we evaluated the potential therapeutic effects of n-3 PUFA supplementation in patients with schizophrenia. Material and methods. The PRISMA guidelines were followed in conducting this systematic review. The Embase, MEDLINE, Web of Science, and Google Scholar databases were searched electronically. The first search yielded 50 papers in total. Subse quently, 43 publications that did not meet our eligibility requirements were removed, and seven articles were selected. Analysis of the literature. The analysis showed that n-3 PUFA supplementation and the placebo group both decreased their psychotic (PANSS and GAF scales) and Calgary Depression Scale symptomatology and boosted their functional ability (GAF) when used as an adjuvant to antipsychotic medication. When administered as a monotherapy with a metabolic antioxidant, n-3 PUFA supplementation proved beneficial for treating schizophrenia. In patients with schizophrenia, n-3 PUFAs have thera peutic benefits as adjuvant treatments to medications, although not for different variables or patient groups. Conclusion. In many studies, patients with chronic schizophrenia who received n-3 PUFA supplementation showed no improvement in their clinical condition.
Słowa kluczowe
docosahexaenoic acid , eicosapentaenoic acid , omega-3 polyunsaturated fatty acids , schizophrenia , supplementation
European Journal of Clinical and Experimental Medicine T. 22, z. 1 (2024), s. 172–178